Glucotrack, Inc. (GCTK): Entry into a Material Definitive Agreement
Glucotrack, Inc. (GCTK) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. false 0001506983 0001506983 2026-07-22 2026-07-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
How this was made
The 30-second read
Why it matters
This 8-K reports a further restructuring: the company partitions the remaining original note and allows the investor to exchange the partitioned note for common stock using a minimum-price formula, subject to a beneficial ownership limit.
Market read
Traders should treat this as a dilution and financing-structure update, with the key variable being how much of the partitioned note the investor converts and at what effective minimum price.
What to watch
The 9.99% beneficial ownership cap can slow or tranche exchanges; also, the minimum price uses the lower of prior close or a 5-day average, which can affect effective conversion economics depending on recent volatility.
Background
Glucotrack previously issued a promissory note to an investor in September 2025, with subsequent reductions via earlier exchange agreements in April 2026.
Ticker impact
Glucotrack entered an exchange agreement that partitions a $3.6M note into a $900k note exchangeable into common stock at a formula-based minimum price.
Near-term impact likely modest unless the market infers heavy near-term note-to-equity conversion; longer-term risk is dilution and potential overhang.
The 8-K is a primary disclosure of the exchange terms (partitioned note, exchange shares calculation, 9.99% beneficial ownership cap). It does not state the total number of shares to be issued or the pace of exchanges, limiting precision on immediate price impact.
Market effects
Adds another example of small-cap financing via note-to-equity exchange mechanics, which can pressure sentiment around similar microcap issuers.
No clear regional spillover beyond Nasdaq-listed small-cap credit and dilution risk perception.
Limited global relevance; the disclosure is company-specific and not tied to macro or international counterparties.
Counterpoint
If the investor does not exchange aggressively, the dilution overhang may be limited, making the market reaction potentially overstated versus the actual conversion pace.
Key entities
- issuerGlucotrack, Inc.
Nasdaq-listed company entering the exchange agreement and issuing exchange shares under the terms described.
- counterpartyInvestor
Holds the promissory note and has the right to exchange all or part of the partitioned note for common stock, subject to the 9.99% cap.
